CL2012003462A1 - Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit. - Google Patents

Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit.

Info

Publication number
CL2012003462A1
CL2012003462A1 CL2012003462A CL2012003462A CL2012003462A1 CL 2012003462 A1 CL2012003462 A1 CL 2012003462A1 CL 2012003462 A CL2012003462 A CL 2012003462A CL 2012003462 A CL2012003462 A CL 2012003462A CL 2012003462 A1 CL2012003462 A1 CL 2012003462A1
Authority
CL
Chile
Prior art keywords
implant
composition
buprenorphine
situ
kit
Prior art date
Application number
CL2012003462A
Other languages
English (en)
Spanish (es)
Inventor
Richard L Norton
Andrew Watkins
Mingxing Zhou
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003462(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of CL2012003462A1 publication Critical patent/CL2012003462A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2012003462A 2010-06-08 2012-12-07 Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit. CL2012003462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine

Publications (1)

Publication Number Publication Date
CL2012003462A1 true CL2012003462A1 (es) 2013-04-01

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003462A CL2012003462A1 (es) 2010-06-08 2012-12-07 Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit.

Country Status (32)

Country Link
US (1) US8921387B2 (https=)
EP (3) EP2579874B1 (https=)
JP (2) JP5986072B2 (https=)
KR (1) KR101865689B1 (https=)
CN (1) CN103079544B (https=)
AU (1) AU2011263478B2 (https=)
BR (1) BR112012031290A2 (https=)
CA (1) CA2801676C (https=)
CL (1) CL2012003462A1 (https=)
CO (1) CO6670529A2 (https=)
CY (1) CY1120761T1 (https=)
DK (2) DK3360538T3 (https=)
ES (2) ES2656938T3 (https=)
FI (1) FI3360538T3 (https=)
GB (2) GB2481018B (https=)
HR (1) HRP20180118T1 (https=)
HU (1) HUE038275T2 (https=)
IL (2) IL223488A (https=)
LT (1) LT2579874T (https=)
MX (1) MX339209B (https=)
MY (1) MY171625A (https=)
NO (1) NO2579874T3 (https=)
NZ (1) NZ604026A (https=)
PL (1) PL2579874T3 (https=)
PT (1) PT2579874T (https=)
RS (1) RS56820B1 (https=)
RU (1) RU2607498C2 (https=)
SG (1) SG186200A1 (https=)
SI (1) SI2579874T1 (https=)
SM (1) SMT201800038T1 (https=)
WO (1) WO2011154724A2 (https=)
ZA (1) ZA201209233B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
KR102196741B1 (ko) 2012-04-17 2020-12-30 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
NZ704012A (en) * 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
WO2014093907A1 (en) * 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
CN105358129A (zh) * 2013-03-15 2016-02-24 赫伦治疗有限公司 聚原酸酯和质子惰性溶剂的组合物
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
ES2837149T3 (es) * 2014-04-21 2021-06-29 Heron Therapeutics Inc Composiciones de un poliortoéster y un excipiente de ácido orgánico
CA2946281C (en) 2014-04-21 2022-12-13 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
NZ731309A (en) * 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
EP4374861A3 (en) 2015-11-16 2024-08-07 MedinCell S.A. A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
TWI743193B (zh) 2016-09-13 2021-10-21 昱展新藥生技股份有限公司 丁基原啡因緩釋製劑
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
EP3638240A2 (en) 2017-06-16 2020-04-22 Indivior UK Limited Methods to treat opioid use disorder
EP3743072B1 (en) 2018-01-22 2023-10-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
BR112020016576A2 (pt) * 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
EP3863712A4 (en) 2018-10-11 2022-07-20 Indivior UK Limited BUPRENORPHINE USED TO TREAT RESPIRATORY DEPRESSION
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
ATE418323T1 (de) * 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
AU2004219595A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
CA2586846C (en) * 2004-11-10 2013-12-31 Qlt Usa Inc. A stabilized polymeric delivery system
HUE025842T2 (en) 2007-02-15 2016-04-28 Tolmar Therapeutics Inc Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
FI3360538T3 (fi) 2023-03-22
ES2939612T3 (es) 2023-04-25
EP4218720A1 (en) 2023-08-02
EP3360538B1 (en) 2023-02-15
KR101865689B1 (ko) 2018-06-08
NO2579874T3 (https=) 2018-06-09
WO2011154724A9 (en) 2012-08-16
GB201413064D0 (en) 2014-09-03
MX2012014335A (es) 2013-03-05
SI2579874T1 (en) 2018-03-30
AU2011263478B2 (en) 2015-01-22
EP2579874B1 (en) 2018-01-10
GB2513267A (en) 2014-10-22
GB2481018A (en) 2011-12-14
DK2579874T3 (da) 2018-01-29
HRP20180118T1 (hr) 2018-03-09
ES2656938T3 (es) 2018-03-01
LT2579874T (lt) 2018-02-12
IL254417A0 (en) 2017-11-30
GB2481018B (en) 2015-03-18
CA2801676C (en) 2018-08-07
CY1120761T1 (el) 2019-12-11
AU2011263478A1 (en) 2013-01-10
JP2013533230A (ja) 2013-08-22
GB201009549D0 (en) 2010-07-21
HUE038275T2 (hu) 2018-10-29
US8921387B2 (en) 2014-12-30
RS56820B1 (sr) 2018-04-30
SG186200A1 (en) 2013-01-30
BR112012031290A2 (pt) 2016-11-01
EP3360538A1 (en) 2018-08-15
US20130210853A1 (en) 2013-08-15
JP2016155865A (ja) 2016-09-01
IL223488A (en) 2017-10-31
CN103079544B (zh) 2017-06-09
GB2513267B (en) 2015-03-18
PT2579874T (pt) 2018-01-29
CA2801676A1 (en) 2011-12-15
NZ604026A (en) 2015-01-30
MY171625A (en) 2019-10-21
PL2579874T3 (pl) 2018-05-30
ZA201209233B (en) 2014-04-30
RU2607498C2 (ru) 2017-01-10
RU2012157244A (ru) 2014-07-20
KR20130135026A (ko) 2013-12-10
CO6670529A2 (es) 2013-05-15
CN103079544A (zh) 2013-05-01
JP5986072B2 (ja) 2016-09-06
WO2011154724A2 (en) 2011-12-15
JP6251774B2 (ja) 2017-12-20
MX339209B (es) 2016-04-15
DK3360538T3 (da) 2023-03-06
EP2579874A2 (en) 2013-04-17
SMT201800038T1 (it) 2018-03-08
WO2011154724A3 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CL2012003462A1 (es) Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit.
AR071297A1 (es) Sistemas de fluidos limpios para fracturacion de monocapa parcial
BRPI1015966A2 (pt) "método para tratar uma formação subterrânea, e, meio de armazenamento legível por computador."
BRPI0821119B8 (pt) composição, método para preparar um artigo, método para preparar uma composição, e método para contatar uma formação subterrânea com uma composição fluida
BRPI0915432A2 (pt) célula de eletrólise, e, método para eletrolisar um líquido.
BR112012002608A2 (pt) composição lubrificante, e, método para melhorar o desempenho de uma composição lubrificante.
BRPI1014319A2 (pt) sistema para minimizar perda de circulação associada com a operação de um reservatório subterrâneo, e, método implementado por computador.
BR112014016408A8 (pt) método para perfuração em uma formação subterrânea, e, fluido de perfuração
BRPI0811319A2 (pt) Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
EP2419680A4 (en) SYSTEMS FOR COST-EFFICIENT CONCENTRATION AND USE OF SOLAR ENERGY
CL2008002066A1 (es) Metodo para estimar probabilidad de duracion de excavadoras mineras electricas sobre la base de cargas acumulativas de cucharones dentados.
BRPI0918234A2 (pt) fundacao de unidade offshore, unidade offshore, metodo para construcao de unidade offshore
EP4509163A3 (en) Graft anchor devices, systems, and methods
BR112012032962A2 (pt) composição para utilização em um furo de poço, composição em gel para utilização em um furo de poço, e método.
BRPI0922294A2 (pt) método para o monitoramento do desgaste de brocas cortadoras de rochas.
BR112012005621A2 (pt) embalagem com vedações de lâmina e recurso de penetração
IN2014CN03185A (https=)
MX343651B (es) Masilla osea.
AR087483A1 (es) Carbonato de calcio con tratamiento de superficie para la union y biorremediacion de composiciones que contienen hidrocarburos
BRPI1014355A2 (pt) método para determinar umidificabilidade de uma zona de formação de solo em torno de um poço.
PT2732157T (pt) Depósito de acumulação de pressão elástica, hidráulica ou pneumática e sua aplicação em instalações de energia eólica
DK2419572T3 (da) Fremgangsmåde til injektion af overfladevand i jorden
PT2785921T (pt) Conexão cilíndrica acafelada utilizando superfícies de apoio para fundações monoestaca offshore
BR112012004128A2 (pt) método para uso em um furo de poço, e, composição para uso em uma formação subterrânea
BRPI1007841A2 (pt) método para estabilizar um aterro ou uma pilha de entulho sobre solo macio, flexível, compatível, e, aterro ou pilha de entulho